Vera Therapeutics
VERA | NASDAQ
$26.97
-$1.13 (-4.02%)
At close: Nov 16, 2026, 4:00 PM ET
$26.85
-$0.12 (-0.44%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Vera Therapeutics Company Profile
Company profile explainedCompany Profile
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Key Executives
| Name | Position |
|---|---|
| Marshall Fordyce | Founder, President, Chief Executive Officer & Director |
| Jane Wright-Mitchell | Chief Legal Officer & Secretary |
| Sean Grant | Chief Financial Officer |
| David L. Johnson | Chief Opearating Officer |
| Debra Charlesworth | Vice President of Corporate Communications |
| Emma Haywood | Vice President of Marketing |
| Joseph R. Young | Senior Vice President of Finance & Chief Accounting Officer |
| Robert Brenner | Chief Medical Officer |
| S. Sandra Park | Senior Vice President of Legal, Healthcare,Commercial Law, Compliance & Operations |
| Tom Doan | Executive Vice President of Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 17, 2026 | 4 | Filing |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 14, 2026 | 4 | Filing |
| Sep 04, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 12, 2026 | 4/A | [Amend] Filing |
| Aug 12, 2026 | 4/A | [Amend] Filing |
| Aug 12, 2026 | 4/A | [Amend] Filing |
| Aug 10, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | 8-K | Current Report |
Vera Therapeutics
| Country | United States |
| IPO Date | May 14, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 361 |
| CEO | Marshall Fordyce |
Contact Details
2000 Sierra Point Parkway Brisbane,
California 94005 United States
Stock Details
| Ticker Symbol | VERA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001831828 |
| CUSIP Number | 92337R101 |
| ISIN Number | US92337R1014 |
| SIC Code | 2834 |
Recent News
- 4 days ago / 247wallst.comHe Takes a New Job at 64 With a $100,000 Stock Grant. When the Shares Vest, Social Security Could Withhold His Retirement Checks Even Though He Hasn’t Sold a Single Share
- 10 days ago / marketbeat.comVera Therapeutics Q3 Earnings Call Highlights
- 11 days ago / seekingalpha.comVera Therapeutics, Inc. (VERA) Q3 2026 Earnings Call Transcript
- 11 days ago / zacks.comVera Therapeutics, Inc. (VERA) Reports Q3 Loss, Tops Revenue Estimates
- 15 days ago / globenewswire.comVera Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- 25 days ago / marketbeat.comVera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy Results
- 25 days ago / seekingalpha.comVera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy Transcript
- 26 days ago / globenewswire.comVera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of Medicine
- 28 days ago / globenewswire.comVera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference Webcast
- 2 months ago / globenewswire.comVera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026
Add to Watchlist
Select watchlists to add or remove VERA